Novartis to invest heavily in follow-on biologics, CEO says

05/4/2011 | CNNMoney/Fortune

Novartis CEO Joseph Jimenez said the Swiss drugmaker is ramping up investments in the development of follow-on biologics, among other efforts, to keep pace with generic-drug competition. "We're looking at pathways of particular diseases -- developing drugs that disrupt that pathway and then extending those drugs to other diseases that are influenced by the same molecular pathway," he said.

View Full Article in:

CNNMoney/Fortune

Published in Brief: